ASP Isotopes

ASPI on Nasdaq. ASP Isotopes sells enriched isotopes and natural gas to medical, semiconductor, and energy customers. Market value $369m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-23.3%low

For every $100 of what the whole company costs, it produced $-23.29 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$2.85 a share, 14% above its 1-year low

Over the past year the price has ranged from $2.51 to $14.49.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.0
-0.1
202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: a shortfall of $84 million in the past 12 months, a shortfall of $47 million in the year to December 2025.

Revenue
$0$433,026$4m$24m
Operating margin
n/a-3704.6%-636.0%-251.2%
Debt to equity
n/an/a0.060.07
Shares outstanding
0.05bn0.07bn0.11bn0.15bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.07× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 214% more shares since 2022

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $5 million last quarter, up 328% on a year ago.
  • A loss of $34 million, compared with a loss of $75 million a year ago.
  • It loses 321 cents on each $1 of sales, compared with 720 cents a year earlier.
  • Over the past 12 months it spent $84 million more cash than it brought in, compared with $30 million a year earlier.
  • 68% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$1m
December 2024$1m
March 2025$1m
June 2025$1m
September 2025$5m
December 2025$17m
March 2026$4m
June 2026$5m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$7m
December 2024-$9m
March 2025-$8m
June 2025-$75m
September 2025-$13m
December 2025-$63m
March 2026-$7m
June 2026-$34m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
10 April 2026
Next quarterly (estimated, 10-Q)
13 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 185 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

  • Mann Paul Elliot
    Passive investor
    7.0%−3.8 pts
    Since 31 December 2025
  • BlackRock, Inc.
    Passive investor
    6.6%+1.1 pts
    Since 31 March 2026
  • AK Jensen Investment Management Ltd
    Passive investor
    5.4%−1.2 pts
    Since 30 September 2025
  • at least 5.1%
    (filed with 1 related holder)
    Since 16 January 2026
  • Sold down below 5%
    Since 30 June 2025
  • BNP Paribas Asset Management UK Ltd
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $61,800 of shares on the open market. 7 sold $9m, $7m of it under preset trading plans.

  • Ryan Robert John Andrew
    Director
    Bought
    Date
    30 September 2026
    Shares
    15,000
    Price
    $2.68
    Value
    $40,200
  • Ryan Robert John Andrew
    Director
    Bought
    Date
    28 September 2026
    Shares
    8,000
    Price
    $2.70
    Value
    $21,600
  • Ainscow Robert
    COO
    Sold
    under a preset trading plan
    Date
    8 September 2026
    Shares
    8,438
    Price
    $4.29
    Value
    $36,216
  • Mann Paul Elliot
    Chairman and CEO, Director
    Sold
    under a preset trading plan
    Date
    4 September 2026
    Shares
    83,759
    Price
    $4.10
    Value
    $343,412
  • Mann Paul Elliot
    Chairman and CEO, Director
    Sold
    under a preset trading plan
    Date
    3 September 2026
    Shares
    83,758
    Price
    $3.92
    Value
    $328,331
  • Ainscow Donald George
    EVP, Gen Counsel, Secretary
    Sold
    Date
    2 September 2026
    Shares
    23,678
    Price
    $3.89
    Value
    $92,107
  • Ainscow Robert
    COO
    Sold
    under a preset trading plan
    Date
    2 September 2026
    Shares
    25,000
    Price
    $3.90
    Value
    $97,625
  • Mann Paul Elliot
    Chairman and CEO, Director
    Sold
    under a preset trading plan
    Date
    2 September 2026
    Shares
    83,758
    Price
    $3.91
    Value
    $327,494
  • Kiessling Heather
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    23,124
    Price
    $6.28
    Value
    $145,219
  • Ainscow Donald George
    EVP, Gen Counsel, Secretary
    Sold
    Date
    30 June 2026
    Shares
    100,000
    Price
    $6.14
    Value
    $614,000

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in ASP Isotopes’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Apr 2026, plus the 10-Q filed 14 Aug 2026 and 21 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on the evaluation of our disclosure controls and procedures as of June 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in connection with our evaluation of our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K (as amended) for the year ended December 31, 2025, our disclosure controls and procedures were not effective as of June 30, 2026.”
    Show the full paragraph
    Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in connection with our evaluation of our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K (as amended) for the year ended December 31, 2025, our disclosure controls and procedures were not effective as of June 30, 2026.

    From the 10-Q filed 14 August 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 32.2% last year. Losing that customer would hurt.

    “Revenues from two customers in our construction services segment represent approximately 32.2% ($7.7 million) and 13.7% ($3.3 million), respectively, of our consolidated revenues for the year ended December 31, 2025.”

    From the 10-K filed 10 April 2026, Item 7A. Market Risk. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.